kdm4

KDM4-IN-4 (compound 47) is a potent inhibitor of histone lysine demethylase 4 (KDM4), with a binding constant of approximately 80 μM for the KDM4A-Tudor domain. It inhibits H3K4Me3 binding to the Tudor domain in cellular contexts with an EC50 value of 105 μM, holding potential for anticancer research applications [1].

KDM4-IN-2 is a potent and selective KDM4/KDM5 dual inhibitor with Kis of 4 and 7 nM for KDM4A and KDM5B, respectively.

Zavondemstat (QC8222 free base) is a histone lysine demethylase 4 (KDM4) inhibitor with anticancer and antitumor activity for the study of triple-negative and breast cancers.

SD49-7 is an inhibitor of histone lysine demethylase 4 (KDM4) with an IC50 of 0.19 µM.

KDM4Ligand-Linker Conjugate 1 is a conjugate comprising a KDM4 target protein ligand and a linker, used in the synthesis of PROTACKDM4 degrader-1.

KDM4ligand-1 is a ligand targeting the protein (histone lysine demethylase KDM4) in PROTACs. It can be utilized for the synthesis of PROTACs.

PROTACKDM4 degrader-1 (Compound 11) is a proteolysis-targeting chimera (PROTAC) degrader specifically designed for KDM4. It effectively degrades KDM4A-C while sparing KDM4D. In esophageal cancer cells, PROTACKDM4 degrader-1 demonstrates strong antiproliferative activity, inducing apoptosis and cell cycle arrest, and inhibits lysine demethylation of histone H3.

KDM4-IN-3 is a cell-permeable KDM4 inhibitor that effectively eliminates prostate cancer cells at low micromolar concentrations.

KDM4-IN-I is a novel inhibitor of KDM4.

KDM4D-IN-3 is a small molecule epigenetic inhibitor targeting KDM4D, with an IC50 value of 4.8 μM.

KDM4C-IN-35 is a novel and selective KDM4C inhibitor.

KDM4D-IN-1 is a KDM4D inhibitor (IC50: 0.41±0.03 μM).

KDM4C-IN-1 is a selective and potent KDM4C inhibitor (IC50: 8 nM) with potential anticancer activity.KDM4C-IN-1 inhibits the growth of HepG2 and A549 cells, and can be used for the study of leukaemia.

QC6352 is a selective and effective KDM4C inhibitor (IC50: 35 nM).

KDM2/7-IN-1 (TC-E 5002) is a selective small-molecule inhibitor of the KDM2/7 histone demethylase subfamily, exhibiting IC50 values of 0.2, 1.2, 6.8, 55, 83, >100, and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A, and KDM4A, respectively. KDM2/7-IN-1 inhibits the proliferation of HeLa and KYSE-150 cancer cells in vitro, highlighting its utility in epigenetic and oncology research.

NSC-636819 is a selective KDM4A/KDM4B inhibitor with potential anticancer activity and can be used for prostate cancer research.

IOX1 is the most effective broad-spectrum 2OG oxygenases(including the JmjC demethylases) inhibitor. The IC50 of IOX1 for KDM4A, KDM3A, is 0.6 and 0.1 uM, respectively.

3-pyridine toxoflavin is a potent KDM4C inhibitor, IC50=19nM.

NCGC00244536 (KDM4B Inhibitor B3) is a potent KDM4B inhibitor (IC50: 10 nM).

NCGC00247743 is an inhibitor of histone lysine demethylase KDM4.

10-Bromodecanoic acid (Decanoic acid, 10-bromo-) is a linker used in the synthesis of PROTACs, such as PROTAC KDM4 degrader-1.

NCDM-32B, a novel potent and selective KDM4 inhibitor, impairs viability and transforms phenotypes of basal breast cancer.

Tripartin specifically inhibits the histone H3 lysine 9 demethylase KDM4 in HeLa cells.

CP2 is a useful organic compound for research related to life sciences and the catalog number is T35338.